Summary
EudraCT Number: 2004-005093-24
Sponsor's Protocol Code Number: D791AC00008
National Competent Authority: Lithuania - SMCA 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2005-02-08
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-005093-24/LT/

A. Protocol Information
A.1 Member State Concerned: Lithuania - SMCA
A.2 EudraCT number: 2004-005093-24
A.3 Full title of the trial: Multicentre, open label, extension study of treatment with gefitinib (IRESSA™) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatment
A.4.1 Sponsor's protocol code number: D791AC00008
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: AstraZeneca AB
B.1.3.4	Country: Sweden
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Iressa (gefitinib)
D.3.2 Product code: ZD1839
D.3.4 Pharmaceutical form: Tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: gefitinib
D.3.9.2 Current sponsor code: D791AC00008
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 250 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: This trial is for patients with advanced non-small cell lung cancer who have completed a preceding gefitinib trial (ZD1839IL0709 or ZD1839IL0710) and in the opinion of the investigator may benefit from gefitinib treatment
MedDRA Classification
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: The primary objective of this study is to provide, or continue to provide, gefitinib treatment to patients who have recently participated in other gefitinib clinical studies.
E.2.2 Secondary objectives of the trial: There are no secondary objectives of the study.
E.2.3 Trial contains a sub-study: Information not present in EudraCT
E.3 Principal inclusion criteria: 1.Provision of informed consent
2.Patients who have completed a preceding gefitinib study and in the opinion of the investigator may benefit from gefitinib treatment. Only patients completing the studies listed below are eligible for enrolment in this open label extension protocol.
	1839IL/0709 (250mg dosing)
	1839IL/0710 (250mg dosing) 
3.No more than 14 days have elapsed between the patient completing the preceding gefitinib clinical study and beginning of this study except when agreed by the AstraZeneca physician. 

E.4 Principal exclusion criteria: 1.Known severe hypersensitivity to gefitinib or any of the excipients of this product
2.Pregnancy or breast feeding (women of child-bearing potential).  Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy
3.Any evidence of clinically active interstitial lung disease (patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded)
4.In the opinion of the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease).
5.Withdrawal, at any time, from the preceding gefitinib study.
6.Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John’s Wort
7.Evidence of any significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study
8.Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the investigational site)
9.Previous enrolment in the present study.

E.5 End points
E.5.1 Primary end point(s): There are no endpoints for this study
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: No
E.6.4 Safety: No
E.6.5 Efficacy: No
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: Information not present in EudraCT
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: Yes
E.6.13.1 Other scope of the trial description: Extension Study
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): Yes
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: No
E.8.1.1 Randomised: No
E.8.1.2 Open: No
E.8.1.3 Single blind: No
E.8.1.4 Double blind: No
E.8.1.5 Parallel group: No
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: No
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.5 The trial involves multiple Member States: Yes
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: Yes
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:
E.8.7 Trial has a data monitoring committee: Information not present in EudraCT
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 
E.8.9.1 In the Member State concerned months: 
E.8.9.1 In the Member State concerned days: 

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Information not present in EudraCT
F.3.3.1 Women of childbearing potential not using contraception  
(For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and
did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether
or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the
database on 2005-02-08) : Yes
F.3.3.2 Women of child-bearing potential using contraception: Information not present in EudraCT
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 1
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 176
F.4.2.2 In the whole clinical trial: 533

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2005-03-08
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2005-02-04

P. End of Trial
P. End of Trial Status: Completed

